For press inquiries click here to contact us.
Alumis, Inc. (Alumni)
Alumis’ TYK2 drug succeeds in key psoriasis studies, will seek FDA approval
Business Wire
Aeovian Pharmaceuticals Raises $55 Million to Advance First-in-Class Selective mTORC1 Inhibitor for Tuberous Sclerosis Complex-Related Epilepsy
Foresight Diagnostics (Alumni)
Natera acquires Foresight Diagnostics for up to $450M
Avenzo Therapeutics (Alumni)
Avenzo Raises $60M Series B
Robin Shah
Scaling What Works, Tackling What’s Next: The Future of Thyme Care
Candid Therapeutics (Alumni)
The Endpoints 11: Ken Song and Candid Therapeutics move fast to build the next autoimmune powerhouse
Medical Device Network
Foresight and Roche sign licensing deal for PhasED
Orange County Business Journal
CG Oncology Completes Enrollment for Phase 3 Study
Xaira Therapeutics
Xaira Therapeutics Releases Largest Perturb-Seq Dataset to Power the Virtual Cell
Please see important disclaimers in the Terms section.
